Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

225
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
225
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

242
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
242
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.2K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

T-cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT.

Bone marrow transplantation·2026
Same author

Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.

Bone marrow transplantation·2026
Same author

Waldenström Macroglobulinemia Presenting With Hepatic Lesions: Case Report and Literature Review.

Case reports in hematology·2026
Same author

Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Thrombosis in Low-Risk Polycythemia Vera: Insights From a Large Real-World Cohort.

Hematological oncology·2026

Related Experiment Video

Updated: Jan 11, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K

High Implementation Adherence to Lenalidomide in Multiple Myeloma.

Irina Amitai1,2, Hila Magen1,2, Avi Leader2,3,4

  • 1Division of Hematology, Chaim Sheba Medical Center, Ramat-Gan 5262000, Israel.

Cancers
|November 13, 2025
PubMed
Summary
This summary is machine-generated.

High adherence to lenalidomide (LEN) in multiple myeloma (MM) patients was observed using electronic monitoring. Most patients followed the 21-day on/7-day off cycle, indicating good treatment compliance.

Keywords:
adherencecompliancelenalidomidemultiple myelomaoral anti cancer medications

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.4K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.8K

Related Experiment Videos

Last Updated: Jan 11, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.4K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.8K

Area of Science:

  • Oncology
  • Pharmacology
  • Patient Adherence Research

Background:

  • Adherence to oral anticancer therapies like lenalidomide (LEN) is crucial for multiple myeloma (MM) treatment outcomes.
  • Limited data exists on LEN adherence patterns in real-world clinical practice.
  • Electronic monitoring (EM) is a reliable method for assessing medication adherence.

Purpose of the Study:

  • To quantify lenalidomide adherence in newly diagnosed multiple myeloma patients using electronic monitoring.
  • To identify patterns of non-adherence during lenalidomide treatment cycles.
  • To assess adherence in real-world clinical settings.

Main Methods:

  • Prospective observational study involving lenalidomide-naïve MM patients.
  • Utilized electronic medication event monitoring (MEMS®) to track adherence.
  • Calculated implementation adherence and analyzed predictors of daily adherence.

Main Results:

  • Eighty-five patients were included, with a median age of 68.
  • 75% of patients perfectly adhered to the 21/7-day on/off cycle; median implementation adherence was 100%.
  • Age under 80 and participation in a support group were significant predictors of adherence.

Conclusions:

  • Lenalidomide adherence in multiple myeloma patients is high.
  • Patients demonstrated excellent compliance with prescribed cycles and overall adherence.
  • Electronic monitoring provides valuable insights into real-world oral anticancer therapy adherence.